Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´ë±¸¡¤°æºÏ Áö¿ª ¼ºÀÎÀÇ ¹ÙÀÌ·¯½º¼º °£¿° Ç¥ÁöÀÚ ¾ç¼º·ü¿¡ °üÇÑ ¿¬±¸ A Study on Markers of Viral Hepatitis in Adults Living in Daegu and Gyungbuk Area

´ëÇѼÒÈ­±âÇÐȸÁö 2003³â 41±Ç 6È£ p.473 ~ 479
¼Ò¼Ó »ó¼¼Á¤º¸
¹Ú°æ½Ä/Park KS ÀÌ¿µ¼®/À̼®±Ù/ȲÁØ¿µ/Á¤¿ìÁø/Á¶±¤¹ü/ȲÀç¼®/¾È¼ºÈÆ/¹Ú½Â±¹/Lee YS/Lee SG/Hwang JY/Chung WJ/Cho KB/Hwang JS/Ahn SH/Park SK

Abstract

Background/Aims: In spite of continuous decrease in prevalence of hepatitis B virus (HBV) infection, hepatic diseases including hepatic cancer still are major causes of death in Korea. As a large portion of hepatic diseases is caused by HBV and hepatitis C virus (HCV) in Korea, we reviewed the serologic markers of HBV and HCV in adults in Daegu and Gyungbuk area for the last five years. Then, we compared them with the reported data of other areas. Methods: We studied total 21,291 adults who had received medical examination at health promotion center of Dongsan Hospital from 1997 to 2001. Results: The overall serologic positivity of HBsAg and anti-HCV was 6.1% and 0.9%, respectively. Seven (0.03%) of 21,291 were positive for both HBsAg and anti-HCV. The positivity of HBsAg was higher in male, highest in 4th and 5th decades. It decreased yearly from 1997 to 2001. The positivity of anti-HCV increased with age but there was no difference between both genders or examined years. Conclusions: The overall trend of viral markers in Daegu and Gyungbuk area was not different significantly from previously reported data of other areas.


¸ñÀû: °£ÁúȯÀº Çѱ¹¿¡¼­ Áß¿äÇÑ »ç¸Á¿øÀÎÀ̸ç ÀÌ Áß »ó´ç¼ö°¡ HBV ¹× HCV¿¡ ±âÀÎÇÑ´Ù. ±âÁ¸¿¡ º¸°íµÈ HBV ¹× HCVÀÇ ¾ç¼º·üÀº Áö¿ª ¹× ½Ã±âÀûÀ¸·Î Â÷ÀÌ°¡ ÀÖ´Â ¹Ù, ÀúÀÚµéÀº º»¿ø °Ç°­°ËÁø¼¾ÅÍ¿¡¼­ °ËÁøÀ» ¹ÞÀº ´ë±¸¡¤°æºÏÁö¿ª ¼ºÀÎÀ» ´ë»óÀ¸·Î anti-HBc¸¦ Æ÷ÇÔÇÏ¿© BÇü ¹× CÇü °£¿° Ç¥ÁöÀÚµéÀÇ ¾ç¼º·üÀ» ÈÄÇâÀûÀ¸·Î Á¶»çÇÏ°í ±âÁ¸¿¡ º¸°íµÈ ±âŸ Áö¿ªÀÇ ÀÚ·áµé°ú ºñ±³ÇÏ¿´´Ù. ´ë»ó ¹× ¹æ¹ý: 1997³â 1¿ùºÎÅÍ 2001³â 12¿ù±îÁö º»¿ø¿¡¼­ °Ç°­°ËÁøÀ» ¹ÞÀº ´ë±¸¡¤°æºÏ Áö¿ªÀÇ 20¼¼ ÀÌ»ó ¼ºÀÎ 21,291¸í¿¡ ´ëÇÑ ÀÚ·á Áß ¹ÙÀÌ·¯½º¼º °£¿° Ç¥ÁöÀÚµéÀ» ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù. °á°ú: HbsAg, anti-HBs, anti-HBcÀÇ ¾ç¼º·üÀº °¢°¢ 6.1%(1,289¸í),64.7%(13,781¸í), 62.0%(13,204¸í)¿´°í anti-HCVÀÇ ¾ç¼º·üÀº 0.9%(190¸í)¿´À¸¸ç ÀÌ Áß 7¸í(0.03%)¿¡¼­ HbsAg°ú anti-HCV°¡ ¸ðµÎ ¾ç¼ºÀ̾ú´Ù. HbsAg ¹× anti-HBs°¡ ¸ðµÎ À½¼ºÀÎ 6,252¸í Áß anti-HBc´Â 3,787¸í(60.6%)¿¡¼­ À½¼º, 2,465¸í(39.4%)¿¡¼­ ¾ç¼ºÀ̾úÀ¸¸ç, °í·ÉÀϼö·Ï anti-HBcÀÇ ¾ç¼º·üÀÌ ³ô¾Ò´Ù(20´ëºÎÅÍ 60´ë±îÁö ¼ø¼­´ë·Î 8.2%, 24.0%, 37.2%, 50.7%, 59.7%). Anti-HBs°¡ ¾ç¼ºÀÎ 13,781¸í Áß anti-HBc´Â 4,290¸í(31.1%)¿¡¼­ À½¼º, 9,491¸í(68.9%)¿¡¼­ ¾ç¼ºÀ̾ú´Ù. HbsAgÀÇ ¾ç¼º·üÀº ³²ÀÚ¿¡¼­ ³ô¾ÒÀ¸¸ç(p<0.001) anti-HCV´Â ³²³à°£ Â÷ÀÌ°¡ ¾ø¾ú´Ù. ¿¬·Éº°·Î´Â HbsAgÀÇ °æ¿ì 30´ë¿Í40´ë¿¡¼­ °¢°¢ 6.6%, 6.7%·Î °¡Àå ³ô¾ÒÀ¸³ª ¼ºº°¿¡ µû¶ó »ó´çÇÑ Â÷À̸¦ º¸¿´À¸¸ç anti-HCVÀÇ °æ¿ì ¿¬·ÉÀÌ ³ôÀ»¼ö·Ï ¾ç¼º·üÀÌ ³ô¾Ò´Ù. °Ë»ç³âµµº° HbsAgÀÇ ¾ç¼º·üÀº 1997³âºÎÅÍ 2001³â±îÁö °¢°¢ 7.1%, 6.8%, 6.3%, 5.9%, 5.2%·Î Á¡Â÷ °¨¼ÒÇÏ´Â ¾ç»óÀ̾úÀ¸¸ç anti-HCVÀÇ ¾ç¼º·üÀº °¢°¢ 1.1%, 1.2%,0,9%, 0,7%, 0.8%·Î À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù. °á·Ð: ´ë±¸¡¤°æºÏ Áö¿ª ÁֹεéÀÇ HbsAg ¹× anti-HCVÀÇ ¾ç¼º·üÀº °¢°¢ 6.1% ¹× 0.9%¿´°í HbsAgÀÇ °æ¿ì ³²ÀÚ¿¡¼­ ³ô¾ÒÀ¸¸ç anti-HCVÀÇ ¾ç¼º·üÀº ³²³à°£ Â÷ÀÌ°¡ ¾ø¾ú´Ù. ¿¬·Éº°·Î´Â HbsAgÀÇ ¾ç¼º·üÀº ³²³à¿¡ µû¶ó Â÷ÀÌ´Â ÀÖÁö¸¸ 30-40´ë¿¡¼­, anti-HCVÀÇ ¾ç¼º·üÀº ´ëü·Î °í·ÉÀϼö·Ï ³ô¾Ò´Ù. ¿¬µµº°·Î HBsAgÀÇ ¾ç¼º·üÀº Á¡Â÷ °¨¼ÒÇÏ´Â ¾ç»óÀ̾úÀ¸³ª anti-HCVÀÇ ¾ç¼º·üÀº À¯ÀÇÇÑ Â÷ÀÌ°¡ ¾ø¾ú´Ù. »ó±â °á°úµéÀ» Á¾ÇÕÇØ º¼ ¶§ ´ë±¸¡¤°æºÏ Áö¿ªÀÇ ¹ÙÀÌ·¯½º¼º °£¿° Ç¥ÁöÀÚµéÀÇ ¾ç¼º·üÀº ±âÁ¸¿¡ º¸°íµÈ ±âŸ Áö¿ªÀÇ ÀÚ·á¿Í ºñ±³ÇÏ¿© °æ¹ÌÇÑ ¼öÄ¡»óÀÇ Â÷ÀÌ´Â ÀÖ¾úÁö¸¸ ´ëüÀûÀÎ °æÇâÀº À¯»çÇÑ ¾ç»óÀ̾ú´Ù.

Å°¿öµå

Hepatitis B virus; Hepatitis C virus; Serologic markers; BÇü °£¿° ¹ÙÀÌ·¯½º; CÇü °£¿° ¹ÙÀÌ·¯½º; Ç÷ûǥÁöÀÚ

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

MEDLINE
KCI
KoreaMed
KAMS